Milestone Pharmaceuticals Appoints David Sandoval as General Counsel

New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal spray New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal spray

Milestone Pharmaceuticals has recently made a significant appointment to its executive team by naming David Sandoval as General Counsel and Chief Compliance Officer. This move signals the company's commitment to robust legal and compliance standards as it navigates the evolving pharmaceutical landscape.

David Sandoval brings a wealth of experience in legal and compliance matters, particularly within the healthcare sector. His previous roles and expertise in regulatory affairs will be critical as Milestone Pharmaceuticals continues to advance its innovative drug therapies.

With Sandoval at the helm of the legal department, Milestone Pharmaceuticals aims to enhance its operational integrity and ensure adherence to regulatory requirements. This is crucial for building trust with stakeholders, including investors, healthcare professionals, and patients. The company's focus on compliance will not only mitigate risks but also foster a culture of accountability and transparency.

Moreover, this appointment reflects Milestone's ongoing growth strategy, which includes expanding its product pipeline and exploring new market opportunities. As the company prepares for future developments and potential challenges in the pharmaceutical industry, Sandoval's strategic legal guidance will be invaluable.

Milestone Pharmaceuticals has established itself as a forward-thinking organization dedicated to improving patient outcomes through innovative therapies, and Sandoval's addition to the team is a testament to their proactive approach in strengthening their leadership structure.